Navigation Links
Omthera Pharmaceuticals Announces Record Date and Meeting Date for Special Meeting of Stockholders
Date:6/13/2013

such as "believes," "anticipates," "expects," "continues," "predict," "potential," "contemplates," "may," "will," "likely," "could," "should," "estimates," "intends," "plans" and other similar expressions are forward-looking statements.  All statements other than statements of historical fact are statements that could be deemed forward-looking statements.  Forward-looking statements involve known and unknown risks, assumptions and uncertainties that may cause actual results in future periods to differ materially from those projected or contemplated in the forward-looking statements, and you should not place undue reliance on these statements.  Some of the factors that could cause actual results to differ materially from current expectations are: the ability to consummate the proposed transaction; any conditions imposed on the parties in connection with the consummation of the proposed transaction; the failure of the Company's stockholders to approve the proposed transaction; the ability to obtain regulatory approvals of the proposed transaction; the occurrence of any event, change or other circumstances that could give rise to the termination of the agreement relating to the proposed transaction; the Company's ability to maintain relationships with employees and third parties following announcement of the proposed transaction; the ability of the parties to satisfy the conditions to the closing of the proposed transaction; the risk that the proposed transaction may not be completed in the time frame expected by the parties or at all; and the risks that are described from time to time in the Company's reports filed with the SEC, including the Prospectus, in other of the Company's filings with the SEC from time to time, including Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and on general industry and economic conditions.  If the proposed transaction is consummated, our stockholders will cease to have any equity interest in the C
'/>"/>
SOURCE Omthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
2. Omthera Pharmaceuticals Announces Invitation to Attend Presentation of the Complete Data Sets from its Phase 3 EVOLVE and ESPRIT Clinical Studies
3. Omthera Pharmaceuticals Presents Data From Analysis Of EVOLVE Trial Showing That Epanova Lowers ApoC-III, A Key Predictor of Cardiovascular Risk
4. Omthera Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
5. Omthera Pharmaceuticals, Inc. Announces Closing of Initial Public Offering
6. Covington Advises Omthera Pharmaceuticals on Merger with AstraZeneca
7. Omthera Pharmaceuticals Announces First Quarter 2013 Financial Results
8. Omthera Pharmaceuticals, Inc. Stockholders Seeking More Money, Information in Buyout Should Contact Deans & Lyons Law Firm
9. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
10. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
11. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... THOUSAND OAKS, Calif. , Sept. 2, 2015 ... announced the submission of a Marketing Authorization Application ... the centralized procedure for etelcalcetide (formerly AMG 416) ... adult patients with chronic kidney disease (CKD) on ... first calcimimetic agent that can be administered intravenously. ...
(Date:9/2/2015)... Miss. , Sept. 2, 2015   Gulf Coast Tattoo ... removal services with the cutting-edge Astanza Duality laser in ... unwanted ink erase their tattoo regret and take back control of ... but extends its services to Biloxi ... region. "With tattoo regret being as prevalent as it ...
(Date:9/2/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/6mlrvg/an_introduction ... "An Introduction to Medical Device Software: Regulations and ... conference to their offering. This ... regulations and requirements that apply to Medical Device ... real life examples and state-of- the-art practices identified ...
Breaking Medicine Technology:Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 2Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 3Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 4Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 5Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 6Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 7Gulf Coast Tattoo Removal Delivers Unrivaled Tattoo Removal Results To Biloxi And Gulfport With Astanza Duality 2An Introduction to Medical Device Software: Regulations and Requirements Course - London, UK - November 2-3, 2015 2
... and CAMPBELL, Calif. , May ... sophisticated risk characterization and personalized therapy guidelines for ... of advanced tests, offering an accompanying nutrition program, ... Director stated:  "With appropriate risk characterization and treatment, ...
... May 25 The U.S. Food and Drug Administration approved Lumizyme (alglucosidase ... a rare genetic disorder. , , ... http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) , , , ... an estimated 1 in every 40,000 to 300,000 births. Its primary symptom is ...
Cached Medicine Technology:Health Network Laboratories (HNL) Enters Into License Agreement With Hunter Laboratories to Provide HunterHeart Cardiovascular Disease Management Program. 2FDA Approves New Treatment for Late-Onset Pompe Disease 2FDA Approves New Treatment for Late-Onset Pompe Disease 3
(Date:9/3/2015)... ... September 03, 2015 , ... Global Vision , the world leader in ... its award-winning print and artwork inspection solutions, ScanProof and ArtProof at Packaging ... the Olympia London, booth #F33 , Be the first to get a sneak peek ...
(Date:9/3/2015)... ... September 03, 2015 , ... DiabetesSisters ... pleased to announce the additional of Carol Wysham, MD, to their esteemed Board ... Diana Karczmarczyk, Donna Rice, David Warren, Matt Stella, Tricia Cedotal, Andrea Thomas, Wanda ...
(Date:9/3/2015)... ... ... ProScrub is a set of automated tools that allow Final Cut Pro ... without the use of keyframes. Utilize ProScrub's powerful sliders to determine the number ... to energetic video productions. ProScrub is a Final Cut Pro X ...
(Date:9/3/2015)... Jersey City, NJ (PRWEB) , ... September 03, 2015 , ... ... devices, announced today that AvePoint Perimeter Service Pack (SP) 4 – AvePoint’s ... – has been named a “KMWorld 2015 Trend-Setting Product”. This is the ...
(Date:9/3/2015)... ... 03, 2015 , ... Representatives with State Farm Agent EJ ... Mississippi Gulf Babypalooza on September 19, 2015. , “We will be providing information ... beyond. We will be discussing setting up college funds, offering information specific to ...
Breaking Medicine News(10 mins):Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 2Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 3Health News:Carol H. Wysham, MD, Joins DiabetesSisters Board of Directors 2Health News:FCPX Effects Developer Releases ProScrub for Final Cut Pro X 2Health News:AvePoint Perimeter Named a “KMWorld 2015 Trend-Setting Product” 2Health News:AvePoint Perimeter Named a “KMWorld 2015 Trend-Setting Product” 3Health News:AvePoint Perimeter Named a “KMWorld 2015 Trend-Setting Product” 4Health News:State Farm Agent EJ Roberts to Help Expecting Mothers at the Mississippi Gulf Babypalooza 2
... mass, but long-term effects on vitality unclear, scientists say ... experimental drug can restore the amounts of muscle-linked growth ... shows. , Those on the therapy also gained muscle ... no clear indication that this led to significant improvements ...
... percent versus third quarter last year ... 4:30 p.m. Eastern Time Today, IRVINE, Calif., Nov. 6 ... intravascular temperature,management (IVTM(TM)) therapies for critically ill patients, today reported,on ... and,nine months ended September 30, 2008., Revenue for the ...
... Company Delivers First Month of Positive Gross Profits ... Corporation,(Nasdaq: PODD ), the leader in patch pump ... results for the three,and nine months ended September 30, ... $10.1 million compared to,$3.8 million in the third quarter ...
... November 06, 2008 Down syndrome, the most ... 1-in-700 births in the United States. Additionally, nearly 80 ... birth. , The Centers for Disease Control (CDC), in ... meeting of experts to review the current knowledge of ...
... STEWARTVILLE, Minn., Nov. 6 Rochester Medical,Corporation (Nasdaq: ... and year ended September 30, 2008., The Company ... to $8,437,000 for the fourth quarter of last year. ... $.03 per diluted share,compared to $733,000 or $.06 per ...
... ... Expectations, DENVER, Nov. 6 Air Methods ... 2008.,Revenue increased 32% to $133.8 million from $101.5 million in the year-ago,quarter. ... million in the prior-year nine-month period., For the quarter, net income ...
Cached Medicine News:Health News:Drug Boosts Natural Growth Hormone in Seniors 2Health News:Drug Boosts Natural Growth Hormone in Seniors 3Health News:Drug Boosts Natural Growth Hormone in Seniors 4Health News:Alsius Corporation Reports Record Third Quarter 2008 Financial Results and Business Progress 2Health News:Alsius Corporation Reports Record Third Quarter 2008 Financial Results and Business Progress 3Health News:Alsius Corporation Reports Record Third Quarter 2008 Financial Results and Business Progress 4Health News:Alsius Corporation Reports Record Third Quarter 2008 Financial Results and Business Progress 5Health News:Alsius Corporation Reports Record Third Quarter 2008 Financial Results and Business Progress 6Health News:Alsius Corporation Reports Record Third Quarter 2008 Financial Results and Business Progress 7Health News:Insulet Reports Third Quarter 2008 Results 2Health News:Insulet Reports Third Quarter 2008 Results 3Health News:Insulet Reports Third Quarter 2008 Results 4Health News:Insulet Reports Third Quarter 2008 Results 5Health News:Insulet Reports Third Quarter 2008 Results 6Health News:Insulet Reports Third Quarter 2008 Results 7Health News:Insulet Reports Third Quarter 2008 Results 8Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 2Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 3Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 4Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 5Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 6Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 7Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 8Health News:Air Methods Reports 3Q2008 Results and 4Q2008 Update 2Health News:Air Methods Reports 3Q2008 Results and 4Q2008 Update 3Health News:Air Methods Reports 3Q2008 Results and 4Q2008 Update 4Health News:Air Methods Reports 3Q2008 Results and 4Q2008 Update 5Health News:Air Methods Reports 3Q2008 Results and 4Q2008 Update 6Health News:Air Methods Reports 3Q2008 Results and 4Q2008 Update 7
... The Eppendorf Mastercycler Family offers fast temperature ... for optimal flexibility. Personal cards enable safe ... reliable transfer of individual protocols between different ... for PCR and come with a two-year ...
96 well thermocycler with unique High Temperature Range (HTR) Peltier technology for fastest available heating and cooling rates up to 4C/sec with High Pressure Lid for automated sealing of PCR plate...
... 40 or 96 temperature cyclers, the gradient block ... range of up to 14 or 22 across ... temperature difference of up to 2C between adjacent ... test up to 12 different annealing temperatures in ...
... performance, high sample throughput instrument at a highly ... Flexible block format, a newly designed flexible heated ... Includes a four year or 80,000 Cycle Warranty! ... connected and run through a PC using Gensoft, ...
Medicine Products: